Journal article
ACE and Type 2 Diabetes Risk: A Mendelian Randomization Study
Abstract
OBJECTIVE: To determine whether ACE inhibitors reduce the risk of type 2 diabetes using a Mendelian randomization (MR) approach.
RESEARCH DESIGN AND METHODS: A two-sample MR analysis included 17 independent genetic variants associated with ACE serum concentration in 4,147 participants from the Outcome Reduction with Initial Glargine INtervention (ORIGIN) (clinical trial reg. no. NCT00069784) trial, and their effects on type 2 diabetes risk were …
Authors
Pigeyre M; Sjaarda J; Chong M; Hess S; Bosch J; Yusuf S; Gerstein H; Paré G
Journal
Diabetes Care, Vol. 43, No. 4, pp. 835–842
Publisher
American Diabetes Association
Publication Date
April 1, 2020
DOI
10.2337/dc19-1973
ISSN
0149-5992
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAgedAged, 80 and overAngiotensin-Converting Enzyme InhibitorsCase-Control StudiesDiabetes Mellitus, Type 2FemaleGenetic Predisposition to DiseaseHumansHypertensionMaleMendelian Randomization AnalysisMiddle AgedPeptidyl-Dipeptidase APolymorphism, Single NucleotideRandomized Controlled Trials as TopicRetrospective StudiesRisk FactorsUnited Kingdom